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Abstract
Background: It has been estimated that more than 50% of patients with Neurofibromatosis type
1 (NF1) have neurobehavioral impairments which include attention deficit/hyperactivity disorder,
visual/spatial learning disabilities, and a myriad of other cognitive developmental problems. The
biological mechanisms by which NF1 gene mutations lead to such cognitive deficits are not well
understood, although excessive Ras signaling and increased GABA mediated inhibition have been
implicated. It is proposed that the cognitive deficits in NF1 are the result of dysfunctional cellular
trafficking and localization of molecules downstream of the primary gene defect.
Results: To elucidate genes involved in the pathogenic process, gene expression analysis was
performed comparing the expression profiles in various brain regions for control and Nf1+/-
heterozygous mice. Gene expression analysis was performed for hippocampal samples dissected
from postnatal day 10, 15, and 20 mice utilizing the Affymetrix Mouse Genome chip (Murine 430
2.0). Analysis of expression profiles between Nf1+/-and wild-type animals was focused on the
hippocampus because of previous studies demonstrating alterations in hippocampal LTP in the
Nf1+/- mice, and the region's importance in visual/spatial learning. Network analysis identified links
between neurofibromin and kinesin genes, which were down regulated in the Nf1+/- mice at
postnatal days 15 and 20.
Conclusion: Through this analysis, it is proposed that neurofibromin forms a binding complex
with amyloid precursor protein (APP) and through filamin proteins interacts with a dopamine
receptor (Drd3). Though the effects of these interactions are not yet known, this information may
provide novel ideas about the pathogenesis of cognitive defects in NF1 and may facilitate the
development of novel targeted therapeutic interventions.
Background
Neurofibromatosis type 1 (also known as von Reckling-
hausen disease) is an autosomal dominant disorder with
a prevalence of 1 in 3500, and is characterized by hyper-
pigmented skin macules (café au lait spots), iris tumors
(Lisch nodules), and benign tumors of nerve cells (neu-
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rofibromas) [1]. Other physical complications observed
in NF1 patients include optic pathway gliomas, scoliosis,
macrocephaly, epilepsy, chronic headaches, bending of
the long bones (pseudoarthrosis), and sphenoid wing
dysplasia [2]. Cognitive deficits in spatial learning and
memory also accompany these more physical manifesta-
tions of NF1 [3]. Though mental retardation is not com-
monly seen in NF1 patients, a high proportion of children
Visualization of all expression fluctuations in the hippocampus across the time series Figure 1
Visualization of all expression fluctuations in the hippocampus across the time series.  Visualization of genes in the 
second dataset showing a significant (p ≤ 0.05) fold change of ≥2 between Nf1+/- and wild type mice at one or more time points 
(n = 163). Genes showing increased expression in the mutant model appear in the red portion of the expression color spec-
trum with decreasing genes in the green portion. The normalized intensity is plotted on a log scale versus the postnatal age. 
Each line represents the expression of an individual gene.BMC Neuroscience 2006, 7:22 http://www.biomedcentral.com/1471-2202/7/22
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Table 1: Genes at post natal day 10 showing fold change values of ≥2 between Nf1+/- and wild type mice (p ≤ 0.05).
Probe Set Unigene Fold Change P Value Gene Name Gene Symbol
1421984_at Mm.20911 12.2 0.00205 stanniocalcin 1 Stc1
1422207_at Mm.4835 9.391 0.000624 5-hydroxytryptamine (serotonin) receptor 5A Htr5a
1426141_at Mm.207059 7.518 0.0351 RF-amide G protein-coupled receptor MrgA1
1445983_at Mm.172835 6.707 0.0139 ubiquitin-conjugating enzyme E2A, RAD6 homolog Ube2a
1436615_a_at Mm.2611 6.396 0.0416 ornithine transcarbamylase Otc
1457713_at Mm.2213 6.388 0.0281 excision repair cross-complementing rodent repair deficiency Ercc5
1459730_at Mm.52297 5.653 0.0329 formin binding protein 1 Fnbp1
1446315_at Mm.282039 5.376 0.0362 ATP citrate lyase Acly
1430486_at Mm.341756 4.883 0.0493 RAD51-like 1 (S. cerevisiae) Rad51l1
1425443_at Mm.244858 4.441 0.0239 transcription factor AP-2, delta Tcfap2d
1452431_s_at Mm.235338 4.175 0.0242 histocompatibility 2, class II antigen A, alpha H2-Aa
1433133_at Mm.159671 3.708 0.0269 EDAR (ectodysplasin-A receptor)-associated death domain Edaradd
1429566_a_at Mm.23790 3.69 0.0369 homeodomain interacting protein kinase 2 Hipk2
1426005_at Mm.199008 3.673 0.00896 dentin matrix protein 1 Dmp1
1429668_at Mm.246550 3.67 0.0389 POU domain, class 4, transcription factor 1 Pou4f1
1415861_at Mm.30438 3.651 0.0382 tyrosinase-related protein 1 Tyrp1
1427313_at Mm.287572 3.557 0.0125 prostaglandin I receptor (IP) Ptgir
1435663_at Mm.9213 3.449 0.00753 estrogen receptor 1 (alpha) Esr1
1441957_x_at Mm.205196 3.211 0.0202 stromal cell derived factor receptor 1 Sdfr1
1422038_a_at Mm.261384 3.19 0.0384 tumor necrosis factor receptor superfamily, member 22 Tnfrsf22
1421967_at Mm.200886 3.031 0.0318 UDP-Gal:betaGlcNAc beta 1,4-galactosyltransferase, polypeptide 5 B4galt5
1419085_at Mm.41456 2.949 0.0459 Purkinje cell protein 2 (L7) Pcp2
1456151_at Mm.299073 2.931 0.0198 zinc finger protein 358 Zfp358
1449484_at Mm.32506 2.929 0.00956 stanniocalcin 2 Stc2
1436490_x_at Mm.297440 2.888 0.0446 RAN, member RAS oncogene family Ran
1447786_at Mm.86413 2.684 0.0443 pleckstrin homology, Sec7 and coiled-coil domains 1 Pscd1
1457684_at Mm.277465 2.683 0.0331 heat shock protein 12B Hspa12b
1437571_at Mm.261602 2.572 0.023 hypermethylated in cancer 2 Hic2
1427637_a_at Mm.89935 2.516 0.048 desmocollin 3 Dsc3
1421275_s_at Mm.354761 2.438 0.00644 suppressor of cytokine signaling 7 Socs7
1444641_at Mm.71996 2.351 0.0412 adenylate cyclase 3 Adcy3
1459828_at Mm.1963 2.326 0.00118 serine/arginine repetitive matrix 1 Srrm1
1421660_at Mm.314531 2.323 0.026 sodium channel, voltage-gated, type IX, alpha polypeptide Scn9a
1445314_at Mm.4866 2.302 0.000693 ets variant gene 1 Etv1
1421234_at Mm.332607 2.248 0.0373 transcription factor 1 Tcf1
1442456_at Mm.172679 2.215 0.0262 spermatogenesis associated 5 Spata5
1441483_at Mm.336081 2.153 0.0398 SLIT and NTRK-like family, member 2 Slitrk2
1438597_x_at Mm.196508 2.137 0.0365 mortality factor 4 like 1 Morf4l1
1439428_x_at Mm.247143 2.118 0.0407 GDP-mannose 4, 6-dehydratase Gmds
1459924_at Mm.340818 2.088 0.0306 ATPase, H+ transporting, lysosomal V0 subunit a isoform 1 Atp6v0a1
1425429_s_at Mm.354757 2.003 0.048 hypoxia inducible factor 3, alpha subunit Hif3a
1427040_at Mm.1314 0.499 0.0418 kidney cell line derived transcript 1 Kdt1
1418745_at Mm.139817 0.498 0.0139 osteomodulin Omd
1419230_at Mm.342959 0.49 0.00148 keratin complex 1, acidic, gene 12 Krt1-12
1423170_at Mm.236009 0.487 0.000269 TAF7 RNA polymerase II, TATA box binding protein (TBP)-associated 
factor
Taf7
1419231_s_at Mm.342959 0.487 0.00492 keratin complex 1, acidic, gene 12 Krt1-12
1457306_at Mm.6988 0.483 0.0387 aminolevulinate, delta-, dehydratase Alad
1432834_at Mm.24242 0.475 0.00679 carboxypeptidase B2 (plasma) Cpb2
1449739_at Mm.281464 0.472 0.0126 phosphatidylserine synthase 1 Ptdss1
1460250_at Mm.43375 0.466 0.00542 sclerostin domain containing 1 Sostdc1
1425291_at Mm.4985 0.466 0.00137 forkhead box J1 Foxj1
1442344_at Mm.82680 0.465 0.00971 AP1 gamma subunit binding protein 1 Ap1gbp1
1456247_x_at Mm.18565 0.462 0.0237 LIM domain only 6 Lmo6
1450760_a_at Mm.39999 0.462 0.0157 inhibitor of growth family, member 3 Ing3
1418082_at Mm.10265 0.456 0.0305 N-myristoyltransferase 1 Nmt1
1427612_at Mm.171224 0.444 0.00697 defensin beta 9 Defb9
1439051_a_at Mm.260504 0.442 0.0497 MAP/microtubule affinity-regulating kinase 4 Mark4
1421906_at Mm.12926 0.427 0.0224 peroxisome proliferator activated receptor binding protein PparbpBMC Neuroscience 2006, 7:22 http://www.biomedcentral.com/1471-2202/7/22
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afflicted with NF1 show learning disabilities (30 – 65%)
[3]. These children perform poorly on tasks requiring
developed spatial memory and visual-spatial functioning.
Though the cognitive manifestations of NF1 have been
characterized, no substantial link between the genetic and
cognitive deficits has been formed. In addition, no link
has been shown between specific mutations within the
causative gene and the degree of physical and mental
impairment.
NF1 is caused by a heterozygous loss of function mutation
within the NF1 gene located on chromosome 17q11.2.
The NF1 gene encodes a ubiquitously expressed cytoplas-
mic protein called neurofibromin. The suspected function
of neurofibromin is based on sequence homology to
known GTPase Activating Proteins (GAPs) as well as
through cell biological and functional studies of mutant
neurofibromin [4]. Neurofibromin inactivates Ras (Ras-
GTP) by converting it to Ras-GDP. Loss of neurofibromin
within a cell would thus result in constitutive activation of
the Ras signaling pathway, ultimately resulting in cell
growth. Ras signaling has also been implicated in neuro-
nal activity and synaptic plasticity [5].
It has been hypothesized that neurofibromin may also act
as a modulator of adenylyl cyclase or may facilitate micro-
tubule binding [5]. Studies in drosophila, cultured
murine neurons, and Nf1-/- mouse embryos (E12.5) have
shown that neurofibromin is necessary for the activation
of adenylyl cyclase by pituitary adenylate cyclase activat-
ing peptide (PACAP) [6-9]. Drosophila models deficient
for neurofibromin have also been used to determine if the
learning deficits seen within mammalian samples are
caused by the developmental abnormalities seen in NF1
or if the cognitive defects are due directly to decreased
neurofibromin activity. Heat-shock induced neurofibro-
min was expressed in adult NF1-/- fruit flies, rescuing the
learning deficits, indicating that developmental factors are
not causing the cognitive deficits [10]. Heat-shock
induced cAMP dependent protein kinase (PKA) expres-
sion also rescued the learning deficits in adult NF1-/- fruit
flies, indicating that the cellular defect must be upstream
of PKA within the adenylate cyclase signaling pathway
[10]. In this Drosophila model it is hypothesized that neu-
rofibromin acts as a GAP specific to G-proteins, influenc-
ing the interaction between G-proteins and adenylate
cyclase [10]. The elucidation of auxiliary functions of neu-
rofibromin can be facilitated by further study of such
model organisms containing targeted mutations of the
Nf1 gene (Drosophila and murine systems).
A mouse model of the cognitive deficits associated with
Neurofibromatosis type 1 was first developed in 1994 and
has since been utilized in the investigation and character-
ization of the disease [11,12]. The learning deficits seen in
the Nf1+/- mice include difficulties in spatial learning and
decreased hippocampal long-term potentiation (LTP) [5].
Increased levels of GABA-mediated inhibition have been
1416203_at Mm.18625 0.427 0.0261 aquaporin 1 Aqp1
1444960_at Mm.243855 0.412 0.031 cytochrome P450, family 2, subfamily u, polypeptide 1 Cyp2u1
1424273_at Mm.29119 0.402 0.00623 cytochrome P450, family 2, subfamily c, polypeptide 70 Cyp2c70
1450995_at Mm.2135 0.37 0.0443 folate receptor 1 (adult) Folr1
1418554_at Mm.2857 0.366 0.0107 adrenomedullin receptor Admr
1424713_at Mm.28623 0.36 0.0295 calmodulin-like 4 Calml4
1454866_s_at Mm.44747 0.357 0.00964 chloride intracellular channel 6 Clic6
1449693_at Mm.258589 0.353 0.0446 mitogen activated protein kinase kinase kinase 7 Map3k7
1452546_x_at Mm.221026 0.337 0.0323 defensin beta 11 Defb11
1419662_at Mm.4258 0.332 0.0234 osteoglycin Ogn
1417297_at Mm.328900 0.294 0.0313 inositol 1,4,5-triphosphate receptor 3 Itpr3
1436477_x_at Mm.240224 0.288 0.0103 RAB2, member RAS oncogene family Rab2
1459738_x_at Mm.1114 0.286 0.0425 galactosidase, alpha Gla
1439167_at Mm.281738 0.284 0.0116 peroxisomal trans-2-enoyl-CoA reductase Pecr
1420652_at Mm.216321 0.27 0.0445 arginine-tRNA-protein transferase 1 Ate1
1427560_at Mm.3410 0.259 0.0328 sine oculis-related homeobox 5 homolog (Drosophila) Six5
1435214_at Mm.40016 0.241 0.00726 gap junction membrane channel protein alpha 12 Gja12
1425794_at Mm.209931 0.236 0.0234 polymerase (DNA directed), alpha 2 Pola2
1426151_a_at Mm.272264 0.235 0.0214 syntaxin 3 Stx3
1439878_at Mm.207365 0.208 0.0151 involucrin Ivl
1450805_at Mm.338890 0.202 0.0179 sarcoglycan, delta (dystrophin-associated glycoprotein) Sgcd
1438406_at Mm.194950 0.195 0.00559 scavenger receptor class F, member 2 Scarf2
1439457_x_at Mm.9852 0.189 0.0278 autophagy 12-like (S. cerevisiae) Apg12l
1444680_at Mm.208970 0.171 0.0137 positive cofactor 2, multiprotein complex, glutamine/Q-rich-associated 
protein
Pcqap
1426171_x_at Mm.193478 0.17 0.0166 killer cell lectin-like receptor, subfamily A, member 7 Klra7
1418618_at Mm.2657 0.0828 6.20E-05 engrailed 1 En1
Table 1: Genes at post natal day 10 showing fold change values of ≥2 between Nf1+/- and wild type mice (p ≤ 0.05). (Continued)BMC Neuroscience 2006, 7:22 http://www.biomedcentral.com/1471-2202/7/22
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Table 2: Genes at post natal day 15 showing fold change values of ≥2 between Nf1+/- and wild type mice (p ≤ 0.05)
Probe Set Unigene Fold Change P Value Gene Name Gene Symbol
1425754_a_at Mm.1420 12.45 0.0354 butyrophilin, subfamily 1, member A1 Btn1a1
1418555_x_at Mm.21642 6.649 0.00469 Spi-C transcription factor (Spi-1/PU.1 related) Spic
1420992_at Mm.10279 6.523 0.00774 ankyrin repeat domain 1 (cardiac muscle) Ankrd1
1418358_at Mm.331192 6.182 0.0229 mitochondrial capsule selenoprotein Mcsp
1458958_at Mm.209041 6.01 0.00798 neighbor of Punc E11 Nope
1447392_s_at Mm.276736 5.357 0.0228 carboxypeptidase D Cpd
1450439_at Mm.248353 5.224 0.0198 host cell factor C1 Hcfc1
1435410_at Mm.159608 4.96 0.0419 testicular cell adhesion molecule 1 Tcam1
1454032_at Mm.126079 4.831 0.0386 neuropilin (NRP) and tolloid (TLL)-like 2 Neto2
1438414_at Mm.39703 4.337 0.0381 fukutin related protein Fkrp
1420652_at Mm.216321 4.245 0.0175 arginine-tRNA-protein transferase 1 Ate1
1425069_at Mm.264252 4.15 0.00663 similar to nuclear protein, 25 K – mouse LOC223706
1421515_at Mm.242728 3.998 0.0161 nuclear receptor subfamily 6, group A, member 1 Nr6a1
1447362_at Mm.29133 3.983 0.04 budding uninhibited by benzimidazoles 1 homolog, beta Bub1b
1456697_x_at Mm.22480 3.814 0.0171 cyclin D binding myb-like transcription factor 1 Dmtf1
1422260_x_at Mm.14302 3.75 0.0144 chemokine (C-C motif) receptor 5 Ccr5
1420253_at Mm.201322 3.638 0.0362 dolichol-phosphate (beta-D) mannosyltransferase 1 Dpm1
1427825_at Mm.272223 3.568 0.0202 solute carrier organic anion transporter family, member 1b2 Slco1b2
1458678_at Mm.347976 3.356 0.00654 NADH dehydrogenase (ubiquinone) 1, alpha/beta subcomplex, 1 Ndufab1
1441659_at Mm.151308 3.305 0.0274 D4, zinc and double PHD fingers, family 3 Dpf3
1417015_at Mm.41265 3.094 0.0256 Ras association (RalGDS/AF-6) domain family 3 Rassf3
1418536_at Mm.34421 3.034 0.0147 histocompatibility 2, Q region locus 7 H2-Q7
1437847_x_at Mm.28275 2.999 0.0357 RNA binding motif protein, X chromosome Rbmx
1440837_at Mm.358604 2.771 0.031 histocompatibility 2, O region beta locus H2-Ob
1418595_at Mm.12966 2.751 0.041 plasma membrane associated protein, S3-12 S3-12
1422278_at Mm.327835 2.707 0.00471 dopamine receptor 3 Drd3
1425398_at Mm.371766 2.539 0.0134 histone 1, H2bc Hist1h2bc
1425443_at Mm.244858 2.53 0.0347 transcription factor AP-2, delta Tcfap2d
1419623_at Mm.86657 2.515 0.0308 protease, serine, 21 Prss21
1421359_at Mm.57199 2.51 0.000164 ret proto-oncogene Ret
1450455_s_at Mm.89993 2.504 0.00985 aldo-keto reductase family 1, member C12 Akr1c12
1420710_at Mm.4869 2.422 0.0149 reticuloendotheliosis oncogene Rel
1434885_at Mm.155687 2.357 0.0457 DNA segment, Chr 7, ERATO Doi 413, expressed D7Ertd413e
1451463_at Mm.291372 2.351 0.0344 Rho GTPase activating protein 8 Arhgap8
1416309_at Mm.290015 2.299 0.00369 nucleolar and spindle associated protein 1 Nusap1
1425064_at Mm.250265 2.272 0.00144 aryl hydrocarbon receptor nuclear translocator Arnt
1425721_at Mm.221688 2.245 0.0475 pleckstrin homology domain interacting protein Phip
1421953_at Mm.21048 2.219 0.0017 v-crk sarcoma virus CT10 oncogene homolog (avian)-like Crkl
1426520_at Mm.104932 2.199 0.0211 B-cell translocation gene 4 Btg4
1450104_at Mm.3037 2.172 0.0339 a disintegrin and metalloprotease domain 10 Adam10
1436008_at Mm.371590 2.134 0.00836 tumor protein D52 Tpd52
1419535_at Mm.263706 2.121 0.0243 solute carrier organic anion transporter family, member 6b1 Slco6b1
1420499_at Mm.10651 2.121 0.0318 GTP cyclohydrolase 1 Gch
1451870_a_at Mm.253518 2.011 0.0256 bromodomain containing 4 Brd4
1445886_at Mm.4454 0.497 0.0367 ELK3, member of ETS oncogene family Elk3
1425690_at Mm.218788 0.461 0.0463 beta-1,3-glucuronyltransferase 1 (glucuronosyltransferase P) B3gat1
1441966_at Mm.124567 0.452 0.0279 transient receptor potential cation channel, subfamily M, member 3 Trpm3
1427635_at Mm.30355 0.438 0.0348 kinesin family member 5A Kif5a
1418194_at Mm.271670 0.421 0.0445 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 10
Galnt10
1416239_at Mm.3217 0.42 0.00011 argininosuccinate synthetase 1 Ass1
1449266_at Mm.131408 0.415 0.0128 methyl CpG binding protein 2 Mecp2
1440072_at Mm.210787 0.407 0.021 glucocorticoid induced transcript 1 Glcci1
1430357_at Mm.371563 0.398 0.0139 H3 histone, family 3B H3f3b
1425707_a_at Mm.328720 0.387 0.0192 potassium inwardly-rectifying channel, subfamily J, member 6 Kcnj6
1446185_at Mm.21158 0.353 0.0479 FK506 binding protein 12-rapamycin associated protein 1 Frap1
1422144_at Mm.3510 0.328 0.0259 inhibin beta E Inhbe
1421447_at Mm.303355 0.298 0.000377 one cut domain, family member 1 Onecut1
1449907_at Mm.174133 0.255 0.0278 beta-carotene 15, 15'-dioxygenase 1 Bcdo1BMC Neuroscience 2006, 7:22 http://www.biomedcentral.com/1471-2202/7/22
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linked to these cognitive deficits within the mouse model
and introduction of a GABAA receptor antagonist (Picro-
toxin) into the knockout mouse system restores normal
LTP in the hippocampus [5]. Double knockout mice het-
erozygous for mutations in both the Nf1 and K-ras genes
(Nf1+/-/K-ras+/-) show similar performance on the hidden
water maze task as wildtype mice [5]. Inactivating muta-
tions within the K-ras gene decrease the level of functional
Ras protein within the cells. Observations that the combi-
nation of Nf1 and K-ras mutations in mice results in nor-
mal cognitive function support the link between an
increase in Ras activity and visual-spatial learning deficits.
Ras activity within cells can also be modulated through
the introduction of farnesyl-transferase inhibitors. By
blocking the post-translational farnesylation of Ras pro-
tein in the Nf1+/- mutant mice, performance on visual-spa-
tial tasks are comparable to wildtype mice, rescuing the
phenotype [5].
The detailed mechanism by which diminished function of
neurofibromin protein leads to defects in hippocampal
long term potentiation, and subsequent deficits in cogni-
tion and learning is not fully understood. Some of the
intermediate steps are dependent on gene transcription
and new protein synthesis [13]. It is thus appropriate to
study the cumulative effect of Nf1 gene mutation in the
developing hippocampus, and characterize alterations in
gene expression profiles in this model system. Here we
describe the results of our studies comparing gene expres-
sion profiles in the hippocampi of Nf1+/- and wild type
mice at postnatal ages 10, 15, and 20 days, a time period
that is critical for syanptogenesis and synaptic remodeling
in the hippocampus. Application of new high-resolution
genomic technologies to the Nf1 knock-out mouse model
may provide new insight into the mechanisms behind the
cognitive impairment in humans with Neurofibromatosis
type 1.
Results
Genes showing fold change values of ≥2.0 and corre-
sponding p-values of ≤0.05 were visualized across the
time series (post natal days 10, 15, and 20) (Fig. 1). Figure
1 shows the expression profiles of genes across the time
series and includes only genes which are significantly
changed at a minimum of one time point. Individual lists
of genes significantly changed at each individual time
point are contained in Tables 1, 2, and 3. Four genes were
dysregulated at more than one time point: Ate1, Tcfap2d,
Rad51l1, Arhgap8. The lists of dysregulated genes include
a myriad of genes including enzymes, receptors, channel
molecules, and transcription factors. All raw expression
data is publicly available [14,15].
RT-PCR validation was performed on a select group of
genes showing significantly (p ≤ 0.05) regulated fold
changes of ≥2 fold. As can be seen in Table 4, Affymetrix
microarray fold change values correlate well with the
trend of transcript levels calculated through RT-PCR reac-
tions. Though the exact fold change values are not identi-
cal, the two assays show consistent trends of regulation.
Genes significantly dysregulated at post natal days 10, 15,
and 20 were entered into the GeneGo network developing
program, along with proteins known to be involved in
learning and memory (Tab, ErbB-2, CREB, calcium,
AMPA, SH2, ShcC, NMDA receptor, TrkB, MAPK, CaM
Kinase II, calcineurin, Rho-associated kinase, MAP2,
peripherin, ERK1, ERK2, TARP, PAK3) [16]. A functional
network was created identifying genes within the data set
that are linked to these known mediators of long term
potentiation (LTP).
As expected, the GeneGo networking software identified
direct modulation of Ras activity (here notated H-Ras) by
neurofibromin. The networking program also identified
neurofibromin as a physical binding partner with both
the kinesin heavy chain and amyloid beta precursor pro-
tein (APP) (Fig. 2). While no significant dysregulation of
APP was seen in the data set, members of the kinesin
motor protein family were downregulated in the Nf1+/-
mice at post natal days 15 and 20 (Tables 2 and 3).
Gene expression analysis shows a 2.7 fold increase in the
expression of dopamine 3 receptor in Nf1+/- brains at post
natal day 15. The GeneGo network development software
highlights binding properties between this dopamine
receptor and filamin A, a protein involved in cytoskeleton
organization through binding with integrins, receptors,
and second messengers [17]. The associations between
integrins and filamin A and between integrins and APP
seen in the GeneGo network links neurofibromin to the
dopamine receptor. Here it is hypothesized that the APP
1421073_a_at Mm.18509 0.237 0.0359 prostaglandin E receptor 4 (subtype EP4) Ptger4
1420296_at Mm.254370 0.232 0.00578 chloride channel 5 Clcn5
1418158_at Mm.20894 0.205 0.0342 transformation related protein 63 Trp63
1448074_at Mm.5033 0.174 0.0361 relaxin 1 Rln1
1453630_at Mm.271953 0.122 0.00471 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 14
Galnt14
1446162_at Mm.125979 0.0938 0.0101 poly A binding protein, cytoplasmic 5 Pabpc5
Table 2: Genes at post natal day 15 showing fold change values of ≥2 between Nf1+/- and wild type mice (p ≤ 0.05) (Continued)BMC Neuroscience 2006, 7:22 http://www.biomedcentral.com/1471-2202/7/22
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and integrin proteins are essential for the transport of the
dopamine receptor protein down the axon via the filamin
proteins. Several other genes linked to intracellular struc-
ture and protein trafficking were also dysregulated in the
dataset. Aberrant movement of these complexes within
the neurons could lead to abnormal localization or abun-
dance of receptors in neuronal processes.
Discussion
Learning and memory deficits observed in human Neu-
rofibromatosis type 1 patients have been modeled in a
Nf1 gene knock-out murine system showing well charac-
terized spatial learning and memory deficiencies. These
mutant mice exhibit increased levels of activated Ras (Ras-
GTP) and increased GABA mediated inhibition. Research
has shown that the cognitive deficit in this mouse model
can be rescued by inactivating Ras (through genetic mod-
ification or pharmacological treatment) or by blocking
postsynaptic GABA uptake [5].
We used gene expression profiling to investigate the
genetic pathways leading to GABA mediated inhibition,
and to link deficiency of neurofibromin to long term
changes at the synapse. Differentially regulated genes at
postnatal days 10, 15, and 20 were analyzed using
GeneGo networking software. This network analysis iden-
tified direct interactions between NF1, APP, integrins, fil-
amins, and kinesins. Though compound binding
properties were identified in silico, these interactions must
be investigated within the cells including how these inter-
actions affect the activity of each protein or the localiza-
tion of the proteins with the cell. It is known that kinesin
proteins act within the nerve cell to carry proteins and cel-
lular organelles from the cell body down neuronal proc-
esses [18]. Interaction between neurofibromin and
kinesins suggests a mechanism for intracellular localiza-
tion of the neurofibromin/APP complex. Current litera-
ture has identified physical interactions between NF1,
APP, and kinesin-1 integral to vesicle transport in melano-
cytes and neurons. This study proposed that NF1 gene
mutations impair vesicle trafficking through aberrant
kinesin transport of both NF1 and APP [19].
Through network analysis an interaction between APP
and the dopamine 3 receptor (DRD3) was idenified.
DRD3, a member of the G alpha inhibitory G protein cou-
pled receptor family, was also dysregulated in the mutant
mice, showing a 3 fold increase in expression in the hip-
Table 3: Genes at post natal day 20 showing fold change values of ≥2 between Nf1+/- and wild type mice (p ≤ 0.05)
Probe Set Unigene Fold Change P Value Gene Name Gene Symbol
1425947_at Mm.240327 13.26 0.000122 interferon gamma Ifng
1442827_at Mm.38049 4.568 0.0446 toll-like receptor 4 Tlr4
1425478_x_at Mm.240044 4.347 0.0178 ubiquitin-conjugating enzyme E2I Ube2i
1450337_a_at Mm.23788 3.618 0.0132 NIMA (never in mitosis gene a)-related expressed kinase 8 Nek8
1422411_s_at Mm.327088 3.478 0.0376 ribonuclease, RNase A family 3 Rnase3
1422297_at Mm.158264 2.727 0.0381 prefoldin 5 Pfdn5
1438564_at Mm.207360 2.573 0.0405 growth arrest specific 2 Gas2
1433732_x_at Mm.281018 2.313 0.0229 insulin-like growth factor 2, binding protein 3 Igf2bp3
1427816_at Mm.21841 2.306 0.0137 splicing factor, arginine/serine-rich 2 (SC-35) Sfrs2
1452349_x_at Mm.255414 2.149 0.0043 interferon activated gene 205 Ifi205
1418604_at Mm.4351 2.038 0.0134 arginine vasopressin receptor 1A Avpr1a
1438156_x_at Mm.18522 0.496 0.0254 carnitine palmitoyltransferase 1a, liver Cpt1a
1426714_at Mm.131618 0.488 0.00577 DNA segment, Chr 11, ERATO Doi 18 D11Ertd18e
1455332_x_at Mm.330161 0.48 0.00869 Fc receptor, IgG, low affinity IIb Fcgr2b
1450951_at Mm.14910 0.478 0.0373 chondroitin sulfate proteoglycan 6 Cspg6
1423719_at Mm.3783 0.359 0.0127 cDNA sequence U46068 U46068
1419109_at Mm.39968 0.357 0.0432 histidine rich calcium binding protein Hrc
1460746_at Mm.236114 0.356 0.0339 fidgetin-like 1 Fignl1
1433382_at Mm.79127 0.352 0.0427 dynein, axonemal, intermediate chain 1 Dnaic1
1449207_a_at Mm.258846 0.297 0.0232 kinesin family member 20A Kif20a
1455990_at Mm.259374 0.279 0.00332 kinesin family member 23 Kif23
1436682_at Mm.3532 0.273 0.0428 thymosin, beta 10 Tmsb10
1430486_at Mm.341756 0.232 0.0143 RAD51-like 1 (S. cerevisiae) Rad51l1
1426598_at Mm.20477 0.222 0.0128 ubiquitously transcribed tetratricopeptide repeat gene, Y chromosome Uty
1451463_at Mm.291372 0.193 0.0173 Rho GTPase activating protein 8 Arhgap8
1441429_at Mm.261591 0.188 0.036 insulin receptor substrate 4 Irs4
1452563_a_at Mm.262676 0.109 0.00609 selected mouse cDNA on the Y Smcy
1457582_at Mm.20477 0.0739 0.0209 ubiquitously transcribed tetratricopeptide repeat gene, Y chromosome Uty
1426438_at Mm.302938 0.0533 0.0444 DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, Y-linked Ddx3yBMC Neuroscience 2006, 7:22 http://www.biomedcentral.com/1471-2202/7/22
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pocampus. The DRD3 receptor is a member of the D2 like
dopamine receptor superfamily which selectively medi-
ates inhibition of adenylate cyclase V [20]. The DRD3
receptor expression has been localized to limbic areas of
the brain, where it acts via the Go subunit and adenylate
cyclase to decrease cAMP levels [20,21]. It is unknown if
alterations in expression of these receptors are involved in
either GABA mediated inhibition, or in other pathways
leading to the phenotypic leaning and memory deficits
characteristic of NF1.
The results of our network analysis are shown in Figure 2,
implying a functional connection between neurofibromin
and the amyloid beta precursor protein/integrin/filamin
complex, which is in turn related to the dopamine recep-
tors (Drd3). These potential interactions between neurofi-
bromin and APP or DRD3 might lead to new ideas about
how neurofibromin is involved in cellular signaling and
synaptic plasticity. Future research should include studies
of APP and related signaling pathways as well as
dopaminergic systems in NF1 models. This also raises the
possibility of investigating these pathways in human
patients using modern imaging modalities (such as posi-
tron emission tomography).
Methods
Animals (breeding, dissection, genotyping, and sexing)
Nf1+/-  mice were purchased from Jackson Laboratory
(symbol  Nf1tm1Fcr) [22]. Breeder pairs were allowed to
mate, and offspring were collected at postnatal days 10,
15, and 20. At these ages, mice were euthanized and bilat-
eral brain regions (hippocampus, cerebral cortex, cerebel-
lum, olfactory bulb, and basal ganglion/thalamus)
dissected and immediately flash frozen in an ethanol/dry
ice bath. Liver and blood were also collected from each
mouse. All tissues were stored at -80°C until RNA or DNA
extraction was performed.
The Nf1+/- mice contain a Neo targeting cassette, which
disrupts the Nf1 gene to form the knockout allele and can
be tested using primers specific for this insert. Genotyping
was performed through a series of PCR reactions contain-
ing one microliter (approximately 100 ng) of sample
DNA, 10 pM of primers, 1× PCR buffer, 2.25 mM MgCl2,
10 mM of each dNTP, and 1 unit of Taq Gold polymerase.
The PCR cycling program started with 95°C for 5 minutes
followed by 35 cycles of 94°C for 1 minute, 55°C for 1
minute, and 72°C for 1 minute. The final step was 72°C
for 10 minutes followed by a 4°C hold. Genotyping and
sexing primers included:
Control primers (1.2 kilobase product):
mMeC.U256 Forward 5'-GTATGATGACCCCACCTTGC
mMeC.L1452 Reverse 5'-TTCAGTCCCTTCCCGCTTTT
Neo specific primers (2 kilobase product):
Neo5' Forward 5'-GCGTGTTCGAATTCGCCAATG
Exon 32 Reverse 5'-GAAGGACAGCATCAGCATG
Y Chromosome specific primers (200 base pair product):
STS162400 Forward 5'GCAAACAACCTCATAGTCCC
STS162400 Reverse 5'CTGGATTTGTGACAAGGAGC
The reaction product was visualized by 2% agarose gel
electrophoresis and the presence of bands noted. The con-
trol PCR reaction detected a segment of the MeCP2 gene
on the X chromosome, and was used to monitor the integ-
rity of template genomic DNA, and the amplification reac-
tion. The presence of a single 2 kb band in the Neo specific
reaction indicated a Nf1+/- heterozygous mouse, whereas
wild type genomic DNA was represented by absence of a
band. Sex was determined by PCR amplification using the
Y-chromosome specific primer set. The presence of a band
at 200 bp indicates a male mouse and females are shown
as the absence of any product.
Affymetrix expression profiling
Four Nf1+/- mice and four age and sex matched wild type
mice were analyzed at each time point. Hippocampi (~20
mg each) from two mice within a single condition were
pooled and divided to yield two identical samples, and
each was individually extracted, labeled, and hybridized
to the Affymetrix (Murine 430 2.0) chip. Total RNA was
isolated from each 40 mg tissue sample using Stratagene
Table 4: Affymetrix and RT-PCR fold change values for genes significantly regulated in the hippocampus of Nf1+/- mice
Gene Symbol Gene Name Probe ID Fold Change P-value RT-PCR Fold 
Change
RT-PCR P-value
Stc1 stanniocalcin 1 1421984_at 12.2 0.0021 1.7592 0.0100
Htr5a 5-hydroxytryptamine (serotonin) receptor 5A 1422207_at 9.391 0.0006 2.0005 0.0580
Neto2 neuropilin (NRP) and tolloid (TLL)-like 2 1454032_at 4.831 0.0386 1.4045 0.0415
Frap1 FK506 binding protein12-rapamycin associated 
protein 1
1446185_at 0.353 0.0479 0.3927 0.4711BMC Neuroscience 2006, 7:22 http://www.biomedcentral.com/1471-2202/7/22
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RTPCR Mini-prep kit (the average yield was 15 µg RNA/40
mg tissue). Extracted RNA was subsequently cleaned using
the Qiagen Mini kit protocol, and the purified RNA was
analyzed through agarose gel electrophoresis to insure
quality.
cDNA was synthesis from 7 µg of purified total RNA, in
vitro transcription, and hybridization proceeded as previ-
ously described [21]. Strict quality controls require that
each RNA sample show >4 × amplification through the in
vitro  transcription protocol, that each scanned array
should contain >30% present calls across the array, and
that the 3'/5' should show consistent values >3 indicating
low nonspecific hybridization. Arrays that do not satisfy
these conditions were not included in the analysis and a
second sample of cRNA was created utilizing a second
allotment of stored total RNA from the sample.
Clustering network connecting neurofibromin primary gene mutation with downstream cellular factors Figure 2
Clustering network connecting neurofibromin primary gene mutation with downstream cellular factors. 
Enlargement of signaling network connecting neurofibromin (Nf-1) with the dopamine 3 receptor (D3DR HUMAN) created 
through the GeneGo networking software. Neurofibromin is indicated as a binding partner for both the kinesin heavy chain 
and amyliod beta precursor protein (APP). APP binds through integrins to filamin A, a cytoskeletal organizational protein which 
in turn can bind to and possibly transport the dopamine 3 receptor.
NF1 NF1BMC Neuroscience 2006, 7:22 http://www.biomedcentral.com/1471-2202/7/22
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Data analysis
Data was extracted from the array images using Affymetrix
Microarray Suite version 5.1 software (MAS5.0). Raw
expression data was corrected for saturation at individual
probes using an in-house Array Data Manipulation pro-
gram which replaces S2 values with S1 values if the S2 val-
ues are greater than 1500 (baseline normalization of 150)
or the S2/S1 signal ratio is less than 0.8.
The modified gene expression data for each individual
array was imported into GeneSpring v 5.0 (Agilent Tech-
nologies). For each time point, average fold changes (rel-
ative to wildtype expression data) were calculated with
error bars. Genes showing expression changes with signif-
icant p-values (p ≤ 0.05) and fold change values of ≥2.0
within at least one time point were exported for func-
tional annotation. Thereafter, the function of each gene
was determined through literature searches, genes were
binned into ontologic categories, and relevant biological
processes and pathways identified.
Modeling the dysfunctional genetic network
The main goal of both temporal and functional clustering
is to generate an integrated pathway beginning with the
known primary genetic defect and ending with proteins
known to be involved in causing the cognitive pathology
under study. This pathway then becomes the template for
later  in vivo validation. The GeneGo network building
algorithms (GeneGo, Inc) were used in an iterative fash-
ion to build gene/protein interaction pathways between
known NF1 pathway members (NF1, Ras, GABA) and
proteins known to be involved in LTP. The gene expres-
sion changes with ≥2 fold differences at p ≤ 0.05 were used
to seed the algorithms and identified new pathway mem-
bers which link the primary defect to the cognitive pheno-
type. All raw expression data is publicly available [14,15].
Validation of the pathogenic cascade
Quantitative Real-Time PCR – Total RNA was extracted
from ~20 mg of hippocampus from 3 Nf1+/- and 3 wild
type mice using the Absolutely RNA Miniprep Kit (Strata-
gene). Reverse transcription reactions were done using 3
µg of total RNA from hippocampus, oligo dT primers, and
the Super Script III First Strand cDNA synthesis kit (Invit-
rogen). Resulting cDNA was amplified on the Chromo4
Four-Color Real-Time System (MJ Research) using the
DyNAmo HS SYBR Green qPCR Kit (Finnzymes) and gene
specific primers. Standardized and optimized primers
were ordered from SuperArray Bioscience Corporation.
These included primers designed for Stc1
(stanniocalcin1), Htr5a (5-hydroxytryptamine (serot-
onin) receptor 5A), Neto2 (neuropilin and tolloid like
protein 2), and Frap1 (FK506 binding protein 12-rapamy-
cin associated protein1). The housekeeping gene GAPD
(glyceraldehydes-3-phosphate dehydrogenase) was ana-
lyzed using the primer set (f-CCAGTATGACTCCACT-
CACG, r-GAGATGATGACCCGTTTGGC). For
amplification, the following program was employed: a
95°C heat activation step for 15 min, followed by 40
cycles of 94°C for 10 sec, 55°C for 25 sec, 72°C for 30 sec,
incubate at 72°C, and plate reads at both 77°C and 81°C.
A melting curve was created evaluating the products
between 60–95°C reading every 0.2°C.
Primer set specificity was verified through melting curve
analysis. The threshold for amplification was set as the
number of cycles necessary to reach logarithmic fluores-
cence accumulation (C(T)). Fold difference in cDNA con-
centration was calculated using the formula F = 2((MH-MG)-
(WH-WG)) where F = fold difference, MH = mutant house-
keeping gene (GAPD) C(T), MG = mutant gene of interest
C(T), WH = wild type housekeeping gene (GAPD) C(T),
WG = wild type gene of interest C(T) [24,25]. Statistical
significance of the resulting fold change values was calcu-
lated with a two-tailed t-test assuming unequal variance.
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